CD200 expression

Treg frequency in BM was significantly increased in CLL advanced stages according to Rai classification. Leukemic cells CD200 and LAIR-1 expression were differently associated with Treg frequency. Increased CD200 expressions on leukemic cells can be considered a sensitive and specific biomarker in detecting CLL progression. As demonstrated by the in-silico research, CD200 blockade targeting may offer therapeutic benefits for CLL treatment through Treg suppression.

Our data underscore novel roles for CD200 in immune evasion as well as therapy resistance in pancreatic cancer. CD200 may represent a novel poor prognostic predictive factor and potential therapeutic target for PDAC with NACRT.

The decrease in both M1 and M2 macrophage markers by calcitriol or their negative correlation with CYP27B1 indicate the modulatory, but rather anticancer activity of VD. The intensity of these effects was the strongest in postmenopausal patients and those without metastases.

Our work provides new mechanistic insights regarding CD200-mediated immunosuppression by gliomas. We demonstrate mechanisms of the druggable glioma-derived CD200 checkpoint on tumor growth and immune suppression.

Furthermore, in signal transduction downstream of CD200 receptor, hCD200 induced Dok2 phosphorylation and suppressed IκB phosphorylation to a greater extent than pCD200. The above data supported the possibility of a significant molecular incompatibility between pCD200 and human CD200 receptor, suggesting that the beneficial effects of hCD200 overexpression in porcine endothelial cells could be mediated by overcoming the molecular incompatibility across the species barrier rather than by simple overexpression effects of CD200.

Additionally, sCD200 correlated with the ratio of circulating matrix metalloproteinase (MMP) 3: tissue inhibitor of metalloproteinase (TIMP) 3 and MMP11/TIMP3. This study highlights the importance of CD200 expression in pancreatic cancer and provides the rationale for designing novel therapeutic strategies that target this protein.

Finally, we demonstrate that CD200 blockade can revive the tumor-killing role of CD11b+CD4+ CTLs and prolong the survival of tumor-bearing mice. Taken together, our study identifies CD11b+CD4+ CTLs in NSCLC with decreased cytotoxicity that can be reinvigorated by CD200 blockade, suggesting that targeting CD200 is a promising immunotherapy strategy in NSCLC.

Regardless, modulating the CD200/CD200R axis has garnered clinical interest as a potential immunotherapeutic strategy for cancer therapy, as demonstrated by early-phase clinical trials. However, further research is necessary to fully understand the complex interactions of CD200 in the tumor microenvironment and to optimize its therapeutic potential in cancer immunotherapy.

By adding CD200 to the combinations of markers in routine testing panel, Immunophenotyping by flow cytometry can be an effective tool in the diagnosis of B-LPDs especially in cases with atypical immunophenotyping pattern. Our result support that CD200 can be added to routine testing panel as it is useful in differentiating them.

To that end, we conducted a translational research, based on BM specimens prospectively collected at our Institution (NCT03357172, NCT03964922), involving patients undergoing allo-HSCT for high-risk MDS and AML and receiving fludarabine/busulfan-based conditioning regimens, anti-lymphoglobuline and cyclosporin/mycophenolate mofetil. Here for the first time, we provide the evidence that MSC senescence plays an pivotal role in defining an altered immune state in transplanted AML possibly shifting the degree of alloreactivity from a high GvH/GvL response (high GvHD and low relapse) to a high immunosuppressive state (low GvHD and high relapse). These findings pave the way for implementing MSC senescence as a biomarker able to predict post-transplant outcomes and show new biological rationales to integrate donor-derived MSC products to better adjust GvH responses.

The difference in the expression patterns of CD117 combined with CD200 shows important value in judging the prognosis of MM patients, and the MM patients with CD117CD200 expression patterns in abnormal plasma cells have a worse prognosis.

In patients, with subsequent progression of the MGUS the initially low expression of CD27, CD19, CD95 and high expression CD56, CD117, CD200 were more often determined. Patients with the CD117 (+) marker, even with the number of tumor PCs in the bone marrow ≤3%, progressed more often (p = 0.001) than patients without this marker. Determining these markers can help identify patients with high risk of MGUS progression.

P3, N=260, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting

Doses in the linear PK range demonstrated sustained peripheral target engagement and 23ME-00610 had a manageable safety profile. The clinical PK, PD, safety, and translational data support evaluation of 23ME-00610 1400 mg Q3W in the ongoing Phase 2a.

Our result shows that different mechanisms of CD200-CD200R can induce different treatment outcomes in combination treatments, namely, only the CD200-CD200R blockade reduces tumor load in melanoma and only the anti-PD-1 and CD200 knockout decrease tumor load in PDAC and HNSCC. Moreover, in melanoma, the CD200-CD200R mainly utilizes the inhibitions on M1 macrophages and dendritic cells to inhibits tumor growth, instead of M2 macrophages.

HeLa cells were injected to induce xenograft tumors in mice, and a CTSK inhibitor, MK-0822, was used to confirm the regulation of CTSK and paclitaxel sensitivity by CD200-CD200R in vivo. In vivo, CTSK inhibition significantly suppressed the effects of CD200-CD200R overexpression on the response to paclitaxel by suppressing the CTSK-mediated NF-κB pathway. CD200-CD200R regulates CTSK-mediated NF-κB pathway to affect cisplatin or paclitaxel sensitivity in cervical cancer, which provides a possible immunotherapeutic target and combination strategy for advanced cervical cancer.

Patients who received intensive chemotherapy (7+3 plus high-dose cytarbine [HiDAC], n=41; azaciticine-venetoxlax [AZA-VEN], n=10) were evaluated; we analyzed the relationship between CD200 expression and complete remission (CR) after first chemotherapy, early relapse (ER), and overall survival (OS)... Expression of CD200 in AML indicates a low remission rate after the first course of chemotherapy and reduces long-term survival in patients receiving chemotherapy alone. HSCT may reduce the adverse effects of CD200 expression in AML patients. Furthermore, CD200 may be a promising future target for immunotherapy.

CD200 expression in myeloid blasts of AML patients could play a role in the development of AML. Analysis of this marker could serve as a prognostic marker and might guide the therapy in AML patients in the future.

These patterns held in murine xenograft models of plasmacytoma, and disseminated bone marrow predominant disease. Our findings underscore the importance of CD200-mediated immune suppression in CAR-T therapy of MM and highlight a promising approach to enhance such therapies by leveraging CD200 expression on aPCs to provide costimulation via a CD200R-CD28 switch.

P3, N=260, Not yet recruiting, The Lymphoma Academic Research Organisation

CD200 expression was remarkably enhanced in CD117+ myeloid naive cells, CD4+ T cells, T cells, activated T cells, CD56dimNK cells, and CD56briNK cells in AML-MRD samples. Our results can be used as important basis for auxiliary diagnosis, prognosis judgment, treatment guidance, and immune regulation in AML.

Thus, AMD3100 qualified as potentially attractive candidate to be included into the therapeutic concept of PCNSL. Beyond therapy, CXCR4-induced suppression of microglial activity is of general neuroimmunological interest and identifies CD200 expressed by the lymphoma cells as a novel mechanism of immune escape in PCNSL.

CD200L was positively significantly correlated with PD-L2 expression and CD137L expression on tumor cells. We confirmed the association between the known immune checkpoint and novel pathways, which is an additional potential target for lung cancer patients and indicates the usefulness of assessing these elements in diagnosis.; Cell and molecular biology; General respiratory patient care

nnMCL patients have an indolent progression, with higher expression rates of CD23 and CD200 and lower expression rates of SOX11, CD5 and CD38. Most patients have IGHV mutations, with a relatively good prognosis, and"watch and wait"approach is an optional treatment.

PD1 CD200 CD4 exhausted T cell may serve as a novel biomarker for poor prognosis and immunotherapy resistance in B. Targeted inhibitors of PD1 CD200 CD4 exhausted T cells may help improve the efficacy of immunotherapy.

MMP14 can be used as a disease characteristic gene of ICC, and may regulate the distribution of immune-infiltrating cells in the ICC tumor microenvironment, which provides a new method for the determination of ICC diagnostic markers and screening of therapeutic targets.

Overall, we conclude that CD200R signaling contributes to unfavorable TME through chemokine-dependent recruitment of immune suppressive neutrophils and exclusion of anti-cancer immune effectors. Our study has implications in developing CD200-CD200R targeted immunotherapy of solid tumors.

CD200 may be a useful immunophenotypic marker in differentiating EBV+ LBCL from CHL, with negative to partial/weak staining favoring a diagnosis of EBV+ LBCL and strong diffuse staining favoring a diagnosis of CHL.

Monocytes mediate NK cell function exhaustion in MDS patients via CD200/CD200R pathway. MDS, NK cell, Monocyte

We analyzed immunohistochemically the expression of CD200/CD200R in tissue samples of 33 advanced melanoma patients in non-resectable stage III or IV and correlated our findings with the treatment response to initial immunotherapy using ICI (ipilimumab, nivolumab, pembrolizumab). Our preliminary data indicate that CD200 expression in primary melanoma has the potential to predict treatment response to ICI. Nevertheless, further studies also including other factors of the tumor microenvironment are needed.

Overall, we conclude that CD200R-mediated signaling, via interaction with CD200 on tumor cells, contributes to unfavorable TME primarily through chemokine-dependent recruitment of immune suppressive neutrophils and exclusion of anti-cancer immune effectors. Our study has significant implications in developing CD200-targeted immunotherapy of solid tumors.

This study showed that CD200 expression was expressed in 100% of the patients. Correlations between CD200 expression and different laboratory data of patients revealed that there was an impact of CD200 on different diagnostic findings. After the follow-up of the patients, we found that the use of PRISM function of the software could add value to the detection of minimal residual disease.

Consistent with qPCR results, immunofluorescence staining confirmed that hepatocellular carcinomas expressed FGL-1 protein. Thus, this study reveals the expression profile of immunoregulatory molecules in canine tumors and opens the door to better understanding the relationship between canine tumors and host immunity.

Tumor burden was analyzed by bioluminescence imaging (log10 fold change [P/sec] 2 weeks after PBMC injection: Control 1,9; treated -0,4; group size = 3). In conclusion the combination of anti CD200 and anti CD123 as prodrugs of an on-target activating trispecific T-cell engager kills AML cells in vitro and in vivo and has the potential to eliminate AML LSC while minimizing the risk for severe on-target off-leukemia toxicity.

The statistical analyses will primarily be descriptive. Participants reflecting the characteristics for the indication-specific cohorts with regards to age, sex, race, and ethnicity, including those from the Black, Latinx/Hispanic and Indigenous communities, will be prioritized for enrollment.

In addition, HBM1047 had a favorable PK profile in mice and exhibited good developability properties. Conclusions In conclusion, HBM1047 represents a novel fully human anti-CD200R1 antagonistic antibody with promising therapeutic potential for the treatment of cancer.

We describe clues to diagnosing CD5/CD10+ LPLs. These cases had a marked male predominance (7:1) and frequent lymphadenopathy without lymphocytosis. Paratrabecular infiltrates and increased mast cells were commonly observed.

We describe clues to diagnosing CD5/CD10+ LPLs. These cases had a marked male predominance (7:1) and frequent lymphadenopathy without lymphocytosis. Paratrabecular infiltrates and increased mast cells were commonly observed.